Cyr Clovis Chua De Imus

Title: Innovations by Cyr Clovis Chua De Imus: Pioneering T-Regulatory Cell Expansion

Introduction

Cyr Clovis Chua De Imus, an accomplished inventor based in Kenmore, WA, has made significant contributions to the field of biotechnology through his innovative work. With a total of two patents to his name, his research is focused on the advancement of immunotherapy, particularly in the realm of T-regulatory cells.

Latest Patents

Cyr Clovis Chua De Imus' latest patents revolve around the development of interleukin-2 (IL-2) muteins designed to enhance the expansion and activation of T-regulatory cells. His patents detail IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes that preferentially activate T-regulatory cells, which are crucial for maintaining immune tolerance. The compositions he has developed are noted for their suitability for large-scale production, enhancing their applicability in therapeutic settings. Additionally, his inventions include variants of human IgG1 Fc molecules that demonstrate high stability and reduced effector function, despite the absence of glycosylation at N297. The methods and linker peptides detailed in his patents further contribute to the efficiency of these compositions when expressed in mammalian cells.

Career Highlights

Cyr is currently associated with Amgen Inc., a leading biopharmaceutical company. His work there has enabled him to push the boundaries of current research in immunology and biotechnology, becoming a vital asset to the company as they develop cutting-edge therapies.

Collaborations

Cyr Clovis Chua De Imus has collaborated closely with notable colleagues, including Eric Alan Butz and Christy Ann Thomson. These partnerships have fostered a dynamic working environment, allowing for the exchange of innovative ideas and strategies that have enriched their collective research outcomes.

Conclusion

Cyr Clovis Chua De Imus exemplifies the spirit of innovation within the biotechnology sector. His patents not only demonstrate his expertise and creativity but also pave the way for advancements in immunotherapy. Through his work at Amgen Inc. and collaborations with skilled professionals, he continues to contribute to the betterment of medical science, particularly in the manipulation and understanding of T-regulatory cells.